Optimizing Antiretroviral Therapy: Addressing Unmet Needs in the Aging HIV Population

Doravirine/islatravir, a newly FDA-approved once-daily 2-drug antiretroviral regimen, offers an effective treatment option for virologically suppressed adults with HIV, with fewer drug interactions and a low cardiometabolic risk important for aging patients. Managing aging-related comorbidities in people living with HIV is increasingly critical as life expectancy approaches that of the general population.

This Wire brief sits within Fusion42's coverage of Health.